View Past PerformanceEcho IQ 대차대조표 건전성재무 건전성 기준 점검 6/6Echo IQ 의 총 주주 지분은 A$17.3M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$18.0M 및 A$718.6K 입니다.핵심 정보0%부채/자본 비율AU$0부채이자보상배율n/a현금AU$11.21m자본AU$17.27m총부채AU$718.61k총자산AU$17.99m최근 재무 건전성 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Nov 25Echo IQ Limited Completes its Clinical Validation for its Heart Failure Clinical Decision Support Software in Collaboration with the Mayo Clinic PlatformEcho IQ Limited announced that it has completed its clinical validation for its heart failure clinical decision support software ("EchoSolv HF") in collaboration with the Mayo Clinic Platform ("MCP"), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software. The clinical validation was designed to evaluate the EchoSolv HF model's ability to detect heart failure on an independent dataset of ~17,000 individual echocardiogram studies. In a major milestone, the primary endpoint of the clinical validation has been met, with results exceeding expectations. The study results show that EchoSolv HF demonstrated outstanding performance in identifying patients with heart failure, achieving a sensitivity of 99.5%. Likewise, the model was accurate in identifying patient that did not have heart failure, achieving a specificity of 91.0%. Completion of the clinical validation marks the final clinical requirement prior to a formal submission for clearance by the US Food & Drug Administration ("FDA"). Echo IQ is now in the process of completing its formal submission to advance the clearance of EchoSolv HF via the FDA's 510(k) regulatory pathway. The Company expects to lodge this submission in the coming weeks. FDA clearance of the solution would allow for EchoSolv HF to be marketed to and used by healthcare professionals in the USA as a clinical decision support software to aid in the detection of heart failure. Heart failure is the leading cause for rehospitalisation in the US and accounts for 17% of all healthcare expenditure in the country. It is now estimated that one in four Americans will develop heart failure in their lifetime. Upon potential FDA clearance of the solution, the Company intends to leverage its existing footprint in the US market to drive uptake of EchoSolv HF.공시 • Nov 13Echo Iq Highlights Market Potential for Echosolv as Following Presentation of New Data for Severe Aortic Stenosis (As) Presented At Aha Scientific Sessions 2025Echo IQ announced that overwhelmingly convincing data from two recent studies have highlighted the significant gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS), and potential for EchoSolv AS to drive improved patient outcomes. The results from both studies were presented separately at the American Heart Association (AHA) Scientific Sessions 2025, which was held in New Orleans, Louisiana. A key takeaway from the study that reviewed echocardiograms for more than 1.2 million patients is that the 'watchful waiting' strategy for moderate-to-severe AS cases is failing many of these patients. In addition, the insights from the results that show how EchoSolv AS was able to identify the severe AS phenotype more accurately than cardiologists, particularly in some subtypes of AS. This study was of particular interest as it showed clearly that the company have work to do in accurately diagnosing women with aortic stenosis and the company are optimistic with the performance of EchoSolv AS to improve the gender equity. Study titled, "Accuracy of cardiologist reporting of severe aortic stenosis vs decision-support artificial intelligence and its impact on clinical management" presented by Dr. Vikas Bhat, University of Notre Dame Australia, this investigator-initiated study compared traditional cardiologist reporting with EchoSolv™?, an AI-powered clinical decision support system. Findings from 30,878 echocardiograms revealed: EchoSolv outperformed cardiologists in identifying severe AS phenotypes, particularly in women and low- gradient cases. Findings underscore the need for policy and clinical practice changes to address treatment gaps and improve survival. This study was funded by an IIS grant from Edwards LifeScience. The funders played no part in the data curation/analysis /preparation of these data. EchoSolv AS is poised to change this paradigm by enabling more precise and consistent identification of high-risk AS patients, thereby supporting clinicians in making informed, timely decisions regarding intervention. Globally, AS is a widespread but frequently underdiagnosed condition, primarily caused by calcification of the aortic valve, which serves as a critical gateway to the heart. Failure to diagnose AS in a timely manner can lead to missed opportunities for lifesaving interventions, such as valve replacement surgery. EchoSolv AS has undergone rigorous validation, including FDA Clearance, through extensive testing across both the United States and Australia, demonstrating the utility of aiding in the accurate diagnosis of patients with aortic stenosis. NEDA principal investigator, Professor David Playford, the senior author for both studies, said: " These studies confirm previous reports in two ways. First, reaffirm that moderate and severe aortic stenosis is a lifethreatening condition that causes significant health service utilization, heart failure hospitalizations and premium mortality. Second, artificial intelligence is capable of outperforming cardiologists in the identification of the set of abnormalities that happen when aortic stenosis progresses toward the severe state. These two findings, taken together, reinforce that EchoSolv AS AI should be considered as a routine option during echocardiographic reporting. Authorised for release by the Board of Directors of Echo IQ Limited.공시 • Sep 30Echo IQ Limited, Annual General Meeting, Nov 18, 2025Echo IQ Limited, Annual General Meeting, Nov 18, 2025.공시 • May 07Echo IQ Limited has completed a Follow-on Equity Offering in the amount of AUD 17.3 million.Echo IQ Limited has completed a Follow-on Equity Offering in the amount of AUD 17.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 56,666,667 Price\Range: AUD 0.3 Discount Per Security: AUD 0.018 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: AUD 0.3 Discount Per Security: AUD 0.018 Transaction Features: Subsequent Direct Listing공시 • Apr 03Echo IQ Provides Update on the Company's Pre-Submission Meeting with the United States Food and Drug Administration Regarding Its Heart Failure Clinical Decision Support SolutionEcho IQ provided an update on the Company's pre-submission meeting with the United States ("US") Food and Drug Administration ("FDA") regarding its heart failure clinical decision support solution ("EchoSolv HF"). The Company is also pleased to announceda collaboration agreement with the Mayo Clinic Platform, part of the Mayo Clinic, a top-ranked US hospital, to undertake Echo IQ's proposed validation study and qualify the Company's artificial intelligence ("AI") heart failure model. The study, expected to commence this quarter, marks the final clinical requirement prior to a formal submission for clearance by the FDA. Echo IQ anticipates FDA clearance for EchoSolv HF during H2 CY2025. Echo IQ requested the pre-submission meeting with the US FDA in December 2024 to verify the design for a proposed validation study which will evaluate EchoSolv HF in its ability to detect various forms of heart failure. The Company undertook the meeting during the first quarter of 2025 and advises that it had positive engagement with the regulator. The engagement has provided the Company confidence to advance the proposed study design of EchoSolv HF's upcoming clinical validation study. Agreement with the Mayo Clinic Platform to undertake validation study and utilisation of EchoSolv HF: Following the pre-submission meeting, the Company executed a collaboration agreement with the Mayo Clinic Platform to undertake the upcoming validation study. Mayo Clinic Platform is focused on earlier diagnoses, more accurate diagnosis and care personalised for each person. Mayo Clinic Platform is creating a world where the best possible care is available to everyone, everywhere. As new technologies create novel opportunities and approaches, Mayo Clinic Platform is harnessing these new technologies to change how care is provided. As part of the agreement, the Mayo Clinic Platform also has the right to utilise EchoSolv HF within the group's network of 30 hospitals, utilise Mayo Clinic Platform's proprietary integration software system alongside the product and co-brand with the Company on its EchoSolv HF and heart failure related materials. The pending validation study will commence this quarter with anticipated completion mid-year. This leaves the Company well placed to meet its proposed timelines for a formal submission to the FDA for regulatory clearance of EchoSolv HF in H2 this calendar year. The agreement with Mayo Clinic Platform provides strong validation of the Company's offering and its potential to positively impact heart failure, which is a widespread condition globally. Heart failure is the leading cause of re-hospitalisation in the US, accounting for 17% of all US healthcare expenditure i. The market for heart failure is estimated to be USD 70 billion annually ii.공시 • Dec 12Echo IQ Limited Appoints Ken Nelson A Non-Executive DirectorEcho IQ Limited advised that US-based healthcare and medical technology executive Mr. Ken Nelson has been appointed a Non-Executive Director, effective 11 December 2024. In line with Mr. Nelson's appointment, Mr. Simon Tolhurst has tendered his resignation from the Board of Directors. Mr. Tolhurst has been a member of the Company's Board since June 2023 and has provided exceptional guidance on Echo IQ's growth trajectory to date, where his specialist expertise was highly valued as part of the Company's successful FDA Clearance. Incoming Director, Mr. Ken Nelson is a leading US-based medical technology and healthcare executive with over 20 years' industry experience. During his career he has been pivotal in leading successful commercialisation efforts with multiple cardiac-focused digital health companies including remote cardiac and diagnostics monitoring business, BioTelemetry, wearable device company, iRhythm and ambulatory ECG solutions monitoring group, Bardy Diagnostics. Currently, he serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator. In addition to this, Mr. Nelson serves as Chairman to the Board of Israeli-based medical technology company, CardiaCare, and is an active Board member of other cardiac-focused digital health and medical technology companies including HeartBeam, Acarix, US-based company Epitel, and European-based platform Happitech. Mr. Nelson also sits on a number of advisory boards and planning committees for early-stage medical technology companies, as well as several industry groups including the Innovation Advisory Board of Heart Rhythm Society, the Health Tech Innovation Business Advisory Board and the Heart & Brain Accelerator of the American Heart Association. Mr. Nelson has an extensive network in the global medical technology sector and strong relationships with a large cohort of sophisticated investors in the healthcare sector. The Company is confident that his expansive network will be beneficial as Echo IQ continues to execute its commercialisation strategy.공시 • Oct 09Echo IQ Limited Announces CEO Changes, Effective 10 January 2025Echo IQ Limited that senior healthcare executive, Mr. Dustin Haines, has been appointed as Chief Executive Officer, effective 10 January 2025 and will be based in the US to spearhead the Company's strategy. Mr. Haines has exceptional experience, stemming from a 25-year career in the biotechnology and pharmaceutical sectors. As CEO, Mr. Haines will be focused on executing the Company's stated growth strategy starting with commercialization in the US market, which will include obtaining relevant market access and reimbursement of the Company's technology. Mr. Haines has extensive experience with building high performing teams and bringing innovation to the market. His knowledge of the industry is expected to play an important role in the Company's strategy. As previously advised, Echo IQ is in advanced negotiations with multiple large hospital groups, pharmaceutical companies and device manufacturers around the uptake of EchoSolv and is confident Mr. Haines' skillset will assist with executing on these negotiations to grow revenue. Echo IQ also plans to leverage Mr. Haines' extensive network to further broaden its pipeline of opportunities in the US and internationally. Mr. Haines, a US citizen and seasoned American healthcare executive, was most recently Vice President & General Manager of Gilead Sciences, Asia, Middle East, Turkey and Russia. During this time, he led business development across several product categories including infectious disease, oncology and immunology. Prior to his time at Gilead Sciences, he was Chief Commercial Officer at medical technology company, Next Science Limited. Mr. Haines has also spent over a decade in senior roles with both ViiV Healthcare and GSK (GlasxoSmithKline), where he was instrumental in delivering Phase 3 assets through to category leading commercialization. In these roles, Mr. Haines covered Japan, Europe and the US, where he has developed extensive networks. Upon commencement of Mr. Haine's tenure, Mr. Andrew Grover will relinquish the role of interim Managing Director and maintain his role as Executive Chair.공시 • Sep 24Echo IQ Limited, Annual General Meeting, Nov 12, 2024Echo IQ Limited, Annual General Meeting, Nov 12, 2024.재무 상태 분석단기부채: ECHQ.F 의 단기 자산 ( A$13.5M )이 단기 부채( A$718.6K ).장기 부채: ECHQ.F에는 장기 부채가 없습니다.부채/자본 비율 추이 및 분석부채 수준: ECHQ.F 부채가 없습니다.부채 감소: ECHQ.F는 5년 전에 부채가 없었습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: ECHQ.F 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.예측 현금 활주로: ECHQ.F 28.1 1.1 28.1 % 매년.건전한 기업 찾아보기7D1Y7D1Y7D1YSoftware 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 14:33종가2026/05/18 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Echo IQ Limited는 3명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rahul TiwariEastCoast ResearchIain WilkieMorgans Financial LimitedThomas GodfreyOrd Minnett Limited
공시 • Nov 25Echo IQ Limited Completes its Clinical Validation for its Heart Failure Clinical Decision Support Software in Collaboration with the Mayo Clinic PlatformEcho IQ Limited announced that it has completed its clinical validation for its heart failure clinical decision support software ("EchoSolv HF") in collaboration with the Mayo Clinic Platform ("MCP"), a division of the Mayo Clinic, a top ranked US hospital. The MCP Validate program is a unique in-market AI evaluation program which generates an independent and objective report on accuracy, efficacy and susceptibility to bias for AI-based decision software. The clinical validation was designed to evaluate the EchoSolv HF model's ability to detect heart failure on an independent dataset of ~17,000 individual echocardiogram studies. In a major milestone, the primary endpoint of the clinical validation has been met, with results exceeding expectations. The study results show that EchoSolv HF demonstrated outstanding performance in identifying patients with heart failure, achieving a sensitivity of 99.5%. Likewise, the model was accurate in identifying patient that did not have heart failure, achieving a specificity of 91.0%. Completion of the clinical validation marks the final clinical requirement prior to a formal submission for clearance by the US Food & Drug Administration ("FDA"). Echo IQ is now in the process of completing its formal submission to advance the clearance of EchoSolv HF via the FDA's 510(k) regulatory pathway. The Company expects to lodge this submission in the coming weeks. FDA clearance of the solution would allow for EchoSolv HF to be marketed to and used by healthcare professionals in the USA as a clinical decision support software to aid in the detection of heart failure. Heart failure is the leading cause for rehospitalisation in the US and accounts for 17% of all healthcare expenditure in the country. It is now estimated that one in four Americans will develop heart failure in their lifetime. Upon potential FDA clearance of the solution, the Company intends to leverage its existing footprint in the US market to drive uptake of EchoSolv HF.
공시 • Nov 13Echo Iq Highlights Market Potential for Echosolv as Following Presentation of New Data for Severe Aortic Stenosis (As) Presented At Aha Scientific Sessions 2025Echo IQ announced that overwhelmingly convincing data from two recent studies have highlighted the significant gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS), and potential for EchoSolv AS to drive improved patient outcomes. The results from both studies were presented separately at the American Heart Association (AHA) Scientific Sessions 2025, which was held in New Orleans, Louisiana. A key takeaway from the study that reviewed echocardiograms for more than 1.2 million patients is that the 'watchful waiting' strategy for moderate-to-severe AS cases is failing many of these patients. In addition, the insights from the results that show how EchoSolv AS was able to identify the severe AS phenotype more accurately than cardiologists, particularly in some subtypes of AS. This study was of particular interest as it showed clearly that the company have work to do in accurately diagnosing women with aortic stenosis and the company are optimistic with the performance of EchoSolv AS to improve the gender equity. Study titled, "Accuracy of cardiologist reporting of severe aortic stenosis vs decision-support artificial intelligence and its impact on clinical management" presented by Dr. Vikas Bhat, University of Notre Dame Australia, this investigator-initiated study compared traditional cardiologist reporting with EchoSolv™?, an AI-powered clinical decision support system. Findings from 30,878 echocardiograms revealed: EchoSolv outperformed cardiologists in identifying severe AS phenotypes, particularly in women and low- gradient cases. Findings underscore the need for policy and clinical practice changes to address treatment gaps and improve survival. This study was funded by an IIS grant from Edwards LifeScience. The funders played no part in the data curation/analysis /preparation of these data. EchoSolv AS is poised to change this paradigm by enabling more precise and consistent identification of high-risk AS patients, thereby supporting clinicians in making informed, timely decisions regarding intervention. Globally, AS is a widespread but frequently underdiagnosed condition, primarily caused by calcification of the aortic valve, which serves as a critical gateway to the heart. Failure to diagnose AS in a timely manner can lead to missed opportunities for lifesaving interventions, such as valve replacement surgery. EchoSolv AS has undergone rigorous validation, including FDA Clearance, through extensive testing across both the United States and Australia, demonstrating the utility of aiding in the accurate diagnosis of patients with aortic stenosis. NEDA principal investigator, Professor David Playford, the senior author for both studies, said: " These studies confirm previous reports in two ways. First, reaffirm that moderate and severe aortic stenosis is a lifethreatening condition that causes significant health service utilization, heart failure hospitalizations and premium mortality. Second, artificial intelligence is capable of outperforming cardiologists in the identification of the set of abnormalities that happen when aortic stenosis progresses toward the severe state. These two findings, taken together, reinforce that EchoSolv AS AI should be considered as a routine option during echocardiographic reporting. Authorised for release by the Board of Directors of Echo IQ Limited.
공시 • Sep 30Echo IQ Limited, Annual General Meeting, Nov 18, 2025Echo IQ Limited, Annual General Meeting, Nov 18, 2025.
공시 • May 07Echo IQ Limited has completed a Follow-on Equity Offering in the amount of AUD 17.3 million.Echo IQ Limited has completed a Follow-on Equity Offering in the amount of AUD 17.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 56,666,667 Price\Range: AUD 0.3 Discount Per Security: AUD 0.018 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: AUD 0.3 Discount Per Security: AUD 0.018 Transaction Features: Subsequent Direct Listing
공시 • Apr 03Echo IQ Provides Update on the Company's Pre-Submission Meeting with the United States Food and Drug Administration Regarding Its Heart Failure Clinical Decision Support SolutionEcho IQ provided an update on the Company's pre-submission meeting with the United States ("US") Food and Drug Administration ("FDA") regarding its heart failure clinical decision support solution ("EchoSolv HF"). The Company is also pleased to announceda collaboration agreement with the Mayo Clinic Platform, part of the Mayo Clinic, a top-ranked US hospital, to undertake Echo IQ's proposed validation study and qualify the Company's artificial intelligence ("AI") heart failure model. The study, expected to commence this quarter, marks the final clinical requirement prior to a formal submission for clearance by the FDA. Echo IQ anticipates FDA clearance for EchoSolv HF during H2 CY2025. Echo IQ requested the pre-submission meeting with the US FDA in December 2024 to verify the design for a proposed validation study which will evaluate EchoSolv HF in its ability to detect various forms of heart failure. The Company undertook the meeting during the first quarter of 2025 and advises that it had positive engagement with the regulator. The engagement has provided the Company confidence to advance the proposed study design of EchoSolv HF's upcoming clinical validation study. Agreement with the Mayo Clinic Platform to undertake validation study and utilisation of EchoSolv HF: Following the pre-submission meeting, the Company executed a collaboration agreement with the Mayo Clinic Platform to undertake the upcoming validation study. Mayo Clinic Platform is focused on earlier diagnoses, more accurate diagnosis and care personalised for each person. Mayo Clinic Platform is creating a world where the best possible care is available to everyone, everywhere. As new technologies create novel opportunities and approaches, Mayo Clinic Platform is harnessing these new technologies to change how care is provided. As part of the agreement, the Mayo Clinic Platform also has the right to utilise EchoSolv HF within the group's network of 30 hospitals, utilise Mayo Clinic Platform's proprietary integration software system alongside the product and co-brand with the Company on its EchoSolv HF and heart failure related materials. The pending validation study will commence this quarter with anticipated completion mid-year. This leaves the Company well placed to meet its proposed timelines for a formal submission to the FDA for regulatory clearance of EchoSolv HF in H2 this calendar year. The agreement with Mayo Clinic Platform provides strong validation of the Company's offering and its potential to positively impact heart failure, which is a widespread condition globally. Heart failure is the leading cause of re-hospitalisation in the US, accounting for 17% of all US healthcare expenditure i. The market for heart failure is estimated to be USD 70 billion annually ii.
공시 • Dec 12Echo IQ Limited Appoints Ken Nelson A Non-Executive DirectorEcho IQ Limited advised that US-based healthcare and medical technology executive Mr. Ken Nelson has been appointed a Non-Executive Director, effective 11 December 2024. In line with Mr. Nelson's appointment, Mr. Simon Tolhurst has tendered his resignation from the Board of Directors. Mr. Tolhurst has been a member of the Company's Board since June 2023 and has provided exceptional guidance on Echo IQ's growth trajectory to date, where his specialist expertise was highly valued as part of the Company's successful FDA Clearance. Incoming Director, Mr. Ken Nelson is a leading US-based medical technology and healthcare executive with over 20 years' industry experience. During his career he has been pivotal in leading successful commercialisation efforts with multiple cardiac-focused digital health companies including remote cardiac and diagnostics monitoring business, BioTelemetry, wearable device company, iRhythm and ambulatory ECG solutions monitoring group, Bardy Diagnostics. Currently, he serves as partner in the Medtech Advantage Fund, which has an exclusive partnership with Medtech Innovator. In addition to this, Mr. Nelson serves as Chairman to the Board of Israeli-based medical technology company, CardiaCare, and is an active Board member of other cardiac-focused digital health and medical technology companies including HeartBeam, Acarix, US-based company Epitel, and European-based platform Happitech. Mr. Nelson also sits on a number of advisory boards and planning committees for early-stage medical technology companies, as well as several industry groups including the Innovation Advisory Board of Heart Rhythm Society, the Health Tech Innovation Business Advisory Board and the Heart & Brain Accelerator of the American Heart Association. Mr. Nelson has an extensive network in the global medical technology sector and strong relationships with a large cohort of sophisticated investors in the healthcare sector. The Company is confident that his expansive network will be beneficial as Echo IQ continues to execute its commercialisation strategy.
공시 • Oct 09Echo IQ Limited Announces CEO Changes, Effective 10 January 2025Echo IQ Limited that senior healthcare executive, Mr. Dustin Haines, has been appointed as Chief Executive Officer, effective 10 January 2025 and will be based in the US to spearhead the Company's strategy. Mr. Haines has exceptional experience, stemming from a 25-year career in the biotechnology and pharmaceutical sectors. As CEO, Mr. Haines will be focused on executing the Company's stated growth strategy starting with commercialization in the US market, which will include obtaining relevant market access and reimbursement of the Company's technology. Mr. Haines has extensive experience with building high performing teams and bringing innovation to the market. His knowledge of the industry is expected to play an important role in the Company's strategy. As previously advised, Echo IQ is in advanced negotiations with multiple large hospital groups, pharmaceutical companies and device manufacturers around the uptake of EchoSolv and is confident Mr. Haines' skillset will assist with executing on these negotiations to grow revenue. Echo IQ also plans to leverage Mr. Haines' extensive network to further broaden its pipeline of opportunities in the US and internationally. Mr. Haines, a US citizen and seasoned American healthcare executive, was most recently Vice President & General Manager of Gilead Sciences, Asia, Middle East, Turkey and Russia. During this time, he led business development across several product categories including infectious disease, oncology and immunology. Prior to his time at Gilead Sciences, he was Chief Commercial Officer at medical technology company, Next Science Limited. Mr. Haines has also spent over a decade in senior roles with both ViiV Healthcare and GSK (GlasxoSmithKline), where he was instrumental in delivering Phase 3 assets through to category leading commercialization. In these roles, Mr. Haines covered Japan, Europe and the US, where he has developed extensive networks. Upon commencement of Mr. Haine's tenure, Mr. Andrew Grover will relinquish the role of interim Managing Director and maintain his role as Executive Chair.
공시 • Sep 24Echo IQ Limited, Annual General Meeting, Nov 12, 2024Echo IQ Limited, Annual General Meeting, Nov 12, 2024.